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Introduction
The organization of the human genome within the cell nucleus 
is nonrandom (Cremer et al., 2006; Misteli, 2007). Chromo-
somes and individual genes occupy preferential localizations 
relative to each other and to nuclear landmarks such as the nu-
clear envelope (Misteli, 2007; Schneider and Grosschedl, 2007; 
Takizawa et al., 2008b). A convenient and quantifiable indica-
tor of a gene’s location is its position along the axis between 
the center of the nucleus and the nuclear edge, referred to as 
its radial position (Takizawa et al., 2008b). Although the radial 
position of some genes has been linked to their activity (Kosak 
et al., 2002; Chambeyron and Bickmore, 2004; Hewitt et al., 
2004; Takizawa et al., 2008a), the functional relevance of radial 
positioning is not clear (Takizawa et al., 2008b).
The spatial organization of the genome changes during 
physiological processes such as differentiation and development 
(Foster and Bridger, 2005; Takizawa et al., 2008b). Importantly, 
large-scale alterations of spatial organization also occur in path-
ological states (Borden and Manuelidis, 1988; Zink et al., 2004; 
Meaburn et al., 2007). A major hallmark of many cancers, which 
is routinely exploited by pathologists, is the distinctive changes 
to cancer nuclei at the gross level, such as to nuclear shape and 
chromatin texture (Zink et al., 2004). These changes suggest 
there must also be major changes to the spatial genome orga-
nization in cancer nuclei (Zink et al., 2004). Indeed, sporadic 
evidence has suggested spatial genome reorganization in human 
cancer. Human chromosome (HSA) 8 moves toward the nuclear 
periphery in pancreatic cancer (Wiech et al., 2005), and a signifi-
cant fraction of nuclei show changes in the positioning of HSA 
18 and 19 in multiple cancer types (Cremer et al., 2003; Wiech 
et al., 2009). In addition to entire chromosomes, the centromere 
of HSA 17 becomes more internally positioned in breast cancer 
compared with normal tissues (Wiech et al., 2005). 
Little is known about changes in positioning of indi-
vidual genes in cancer cells. In a 3D culture in vitro model   
system of early breast cancer, AKT1, BCL2, ERBB2, and VEGFA 
have been demonstrated to undergo repositioning (Meaburn and 
Misteli, 2008), but it is unclear to what degree similar changes 
occur in cancer tissues. The only reported gene-specific change 
in gene location in cancer tissues is the marginally more peripheral 
position of BCL2 in a BCL2-positive cervical squamous car-
cinoma tissue (Wiech et al., 2009). In contrast, BCL2 did not 
reposition in a BCL2-negative cervical squamous carcinoma 
tissue (Wiech et al., 2009), and ERBB2 was found to not alter 
radial position in a breast cancer tissue (Wiech et al., 2005). 
However, these studies are based on only a single cancer tissue, 
making it difficult to assess how general repositioning events 
are, or if they are random events. Here, we set out to identify 
genes that are frequently differentially positioned in breast can-
cer tissues, and we explore the possibility that disease-specific 
spatial organization of the genome may be used to distinguish 
malignant from normal tissue.
G
enomes are nonrandomly organized within the 
three-dimensional  space  of  the  cell  nucleus. 
Here, we have identified several genes whose 
nuclear positions are altered in human invasive breast 
cancer compared with normal breast tissue. The changes 
in positioning are gene specific and are not a reflection 
of genomic instability within the cancer tissue. Reposi-
tioning events are specific to cancer and do not gen-
erally occur in noncancerous breast disease. Moreover, 
we show that the spatial positions of genes are highly 
consistent between individuals. Our data indicate that 
cancer  cells  have  disease-specific  gene  distributions. 
These interphase gene positioning patterns may be used 
to identify cancer tissues.
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Figure 1.  Spatial reorganization of the genome in cancer. (A) FOLS2 (green) and CSF1R (red), and (B) ERBB2 (green) and MYC (red) are detected by 
FISH in normal or cancer breast tissue. Nuclei were counterstained with DAPI (blue). Projected image stacks are shown. Bars, 5 µm. (C) Cumulative RRDs 
for the indicated genes in cancerous breast tissues (black) and normal tissues (red). n = 88–220 cells.803 Cancer-specific spatial gene positioning • Meaburn et al.
Results
We sought to identify genes that occupy distinct intranuclear   
positions in normal and malignant cells. To this end, we visual-
ized a set of 20 gene loci (Table S1) by FISH in a panel of 11 
normal and 14 invasive carcinoma human breast tissues (Fig. 1,   
A and B; and Table I). The radial position of a gene, normalized 
to the size of the nucleus, was determined using a modified 
version  of  a  previously  developed  image  analysis  method 
(Meaburn and Misteli, 2008; Takizawa et al., 2008a), which takes 
into account the non-elliptical shape of some of the nuclei (see 
Materials and methods). Data from 88–220 nuclei per sample 
(Fig. S1), acquired from multiple randomly selected regions of 
the tissue sample, were analyzed and combined to determine 
the cumulative relative radial distribution (RRD) for each gene 
in a tissue (Figs. 1 C and S2 A). The RRD is a standard measure 
of a gene’s position in a population and is defined as the statisti-
cal distribution of the radial position of all alleles in a cell pop-
ulation (see Materials and methods). RRDs were statistically   
compared with each other using the two-sample 1D Kolmogorov-
Smirnov test (KS test) as described previously (Figs. 2 and 
S2; see Materials and methods; Meaburn and Misteli, 2008; 
Takizawa et al., 2008a). The RRDs were considered distinct 
if P < 0.01. RRDs for a given gene were highly reproducible 
between  experiments  and  were  statistically  indistinguishable 
(0.65 ≤ P ≤ 0.81). The 20 genes mapped to 14 chromosomes 
(Table S1), and were selected randomly and irrespective of their 
function in order to enable an unbiased screening approach.
Low variability of spatial gene positioning 
patterns among individuals
Initially, we determined to what degree spatial gene positioning 
patterns are reproducible between individuals by comparing the 
positions of a subset of genes in morphologically normal breast 
tissue from multiple individuals. 8 out of 15 genes were indis-
tinguishable in all cross-comparisons between normal breast 
tissues (P > 0.01; HSP90AA1, TGFB3, MYC, VEGFA, CCND1, 
HEY1, MMP1, and ZNF217; Figs. 1, 2, and S2; and Table II). 
Table I.  Characterization of breast tissues
Sample code Pathology Other information Source Source specimen ID Tissue thickness
N1 Normal Absence of cancer; 35 y Biomax HuFPT 130 a 5 µm
N2 Normal Absence of cancer; 44 y Biomax HuFPT 129 5 µm
N3 Normal Absence of cancer; 53 y Biomax HuFPT 128 5 µm
N4 Normal Absence of cancer ACSR AA-98-3672 5 µm
N5 Normal Absence of cancer; 56 y BioChain T2234086 5 µm
N6 Normal NAT; 50 y BioChain TMA core A2 4 µm
N7 Normal NAT; 51 y Imgenex IMH-1013 4 µm
N8 Normal NAT (cancer C4) ACSR AA-98-313-Q 5 µm
N9 Normal NAT ACSR AA-96-193-3 5 µm
N10 Normal NAT ACSR AA-97-239-2 5 µm
N11 Normal NAT (cancer C2) ACSR AA-02-161-HH 5 µm
C1 IDC with DCIS ER+ ACSR AA-97-108 B 5 µm
C2 IDC with DCIS Lymph node +, ER, PR-, HER2- ACSR AA-02-161 C 5 µm
C3 IDC Lymph node + ACSR AA-98-31 A 5 µm
C4 IDC with DCIS ER+, PR+, HER2+ ACSR AA-98-313 C 5 µm
C5 IDC with DCIS Moderate to high grade ACSR AA-98-051-2 5 µm
C6 IDC Poorly differentiated ACSR AA-96-152-3 5 µm
C7 IDC TMN stage T4N3M1; 50 y BioChain TMA core C1 4 µm
C8 IDC TMN stage T2N1M0; 43 y BioChain TMA core C2 4 µm
C9 IDC TMN stage T2N3M0; 47 y BioChain TMA core C3 4 µm
C10 IDC TMN stage T2N0M0; 56 y BioChain TMA core C4 4 µm
C11 IDC TMN stage T2N2M0; 34 y BioChain TMA core C5 4 µm
C12 ILC TMN stage T2N0M0 BioChain TMA core D1 4 µm
C13 ILC TMN stage T2N0M0 BioChain TMA core D2 4 µm
C14 ILC Moderately differentiated;  
tumor size: 3 cm diameter; 38 y
Capital CT2235086-3 5 µm
B1 Hyperplasia 41 y BioChain TMA core B1 4 µm
B2 Hyperplasia 23 y, male BioChain TMA core B2 4 µm
B3 Fibroadenoma 45 y BioChain TMA core B3 4 µm
B4 Fibroadenoma 25 y BioChain TMA core B4 4 µm
B5 Fibroadenoma 32 y BioChain TMA core B5 4 µm
B6 Hyperplasia 49 y BioChain TMA core A4 4 µm
IDC, invasive ductal carcinoma; DCIS, ductal carcinoma in situ; ILC, invasive lobular carcinoma; NAT, normal adjacent to breast cancer tissue; y, years old;   
+, positive; , negative; TNM, tumor (graded 0–4, based on tumor size and extension to chest wall or skin), node (lymph node metastasis, numbered as N0 [no 
spread to lymph nodes] or N1–3 [metastasis to lymph nodes]), metastasis (0 = no distant metastasis, 1 = distant metastasis) classification of malignant tumors; Biomax, 
US Biomax, Inc; ACSR, AIDS and Cancer Specimen Resource; Imgenex, Imgenex Corp.; BioChain, BioChain Institute, Inc.; TMA, TMA catalog no. Z7020010; 
Capital, Capital Biosciences, Inc.JCB • VOLUME 187 • NUMBER 6 • 2009   804
Furthermore,  the  positioning  patterns  in  tissue  from  healthy 
individuals (N1–5) were indistinguishable from those in nor-
mal tissues adjacent to the tumor from breast cancer patients 
(N6–11; Figs. 1, 2, and S2; and Table I). Four of nine tested 
genes were indistinguishably located in the two types of normal 
Five genes (HES5, FOSL2, CSF1R, BCL2, and HES1) showed 
a single discrepancy among all cross-comparisons (0.0015 ≤ 
P ≤ 0.0077). Two genes, ERBB2 and AKT1, had a significantly 
different RRD for a single individual (N11 and N5, respec-
tively) compared with the majority of all normal tissues (Fig. 2).   
Figure 2.  Spatial reorganization of the genome in cancer. Pairwise statistical comparisons of cumulative RRDs between individual normal (N1–11) and 
cancerous (C1–14) breast tissues using the two-sample 1D KS test. n = 88–220 cells. Asterisks denote a cross-comparison between a normal and cancer 
specimen from the same individual (see Table I).805 Cancer-specific spatial gene positioning • Meaburn et al.
further analysis on the eight genes with the highest degree 
of repositioning.
For these eight genes, approximately half of the pairwise 
comparisons in a given tumor were consistent between all nor-
mal tissues, with 55/103 comparisons showing either reposi-
tioning of a given locus in a tumor relative to all normal tissues 
(Fig. 2, vertical red/orange columns; 40/103) or no reposition-
ing to all normal tissues (Fig. 2, vertical blue columns; 15/103). 
In two individuals for which both cancer and adjacent normal 
breast tissue were available (Table I; asterisks in Figs. 2 and 
S2), the majority of comparisons of a gene’s position between 
the tumor relative to its corresponding adjacent normal tissue 
showed similar repositioning behavior to that of the tumor com-
pared with the majority of other normal tissues, with only   
4 of 21 comparisons showing a differential positioning behavior. 
Moreover, for 7 of the 21 comparisons, the gene had a signifi-
cantly different RRD in the cancer tissue than in its corresponding 
adjacent normal tissue.
Only a minority of the tested genes underwent significant 
repositioning in a given cancer tissue (Table II), which suggests 
that repositioning is not a reflection of global genome reorgani-
zation but is more gene specific. Furthermore, in several cases, 
genes on the same chromosome behaved differently (Figs. 1, 2, 
and S2; and Table S1). For example, AKT1, HSP90AA1, and 
TGFB3 all map to HSA 14. Although all three genes were re-
positioned in some cancers (C2, C3, C8, and C10) and none of 
them repositioned in another cancer (C12), in yet other cancers, 
only one (C1, C4, C9, and C13) or two (C7, and C11) of the 
three genes repositioned. Differential repositioning behavior of 
genes on the same chromosome was also observed for BRCA1 
samples for all cross-comparisons (Figs. 2 and S2; P > 0.01), 
with a further three genes having only a single significant dif-
ference. The remaining two genes had three cross-comparisons 
that  were  significantly  different.  Collectively,  and  consistent 
with earlier data (Wiech et al., 2005), these observations dem-
onstrate a low degree of variability in spatial gene positioning 
between individuals.
Identification of repositioned genes in 
breast cancer
To identify genes that are repositioned in a wide range of breast 
cancer tissues, we deliberately analyzed the positions of genes 
in a diverse population of invasive breast carcinomas, which in-
cluded both ductal and lobular carcinomas, HER2-positive and 
HER2-negative cancers, cancers that are estrogen receptor (ER)- 
and progesterone receptor (PR)-positive or ER/PR negative, and 
carcinomas that have metastasized to the lymph nodes and tumors 
without known metastases (Table I).
When  multiple  cancer  tissues  were  individually  cross 
compared with multiple normal tissues, six genes (BRAC1, PTEN, 
TJP1, TLE1, HEY1, and BCL2) showed very little change in 
position between normal and cancer breast tissue, and reposi-
tioned in only 0–22% of all possible cross-comparisons (Fig. 2, 
Fig. S2 B, and Table II). Six loci (PTGS2, CCND1, MMP1/3/12, 
VEGFA, ZNF127, and HES1) showed differential positioning 
in 25–50% of cross-comparisons. Seven genes (TGFB3, AKT1, 
ERBB2, CSF1R, HSP90AA1, FOSL2, and MYC) repositioned 
in 53–71% of comparisons (Fig. 2 and Table II). One gene, 
HES5,  repositioned  in  91%  of  the  pairwise  comparisons 
(83/91 tissue comparisons; Fig. 2 and Table II). We focused 
Table II.  Cross-comparisons between individual tissues
Gene Number of cross-comparisons between individual  
normal tissues
Number of cross-comparisons between individual normal  
and cancer tissues
SD Total % SD SD Total % SD
HES5 1 21 4.8 83 91 91.2
MYC 0 15 0.0 47 66 71.2
FOSL2 1 21 4.8 58 91 63.7
HSP90AA1 0 15 0.0 41 66 62.1
CSF1R 1 21 0.0 56 91 61.5
ERBB2 7 36 19.4 73 126 57.9
AKT1 5 21 23.8 54 98 55.1
TGFB3 0 28 0.0 59 112 52.7
HES1 1 3 33.3 6 12 50.0
ZNF217 1 1 0.0 3 6 50.0
VEGFA 0 6 0.0 10 24 41.7
MMP1/3/12 0 1 0.0 2 6 33.3
CCND1 0 6 0.0 7 24 29.2
PTGS2 ND ND ND 1 4 25.0
BCL2 1 3 33.3 4 18 22.2
HEY1 0 3 0.0 1 15 6.7
BRCA1 ND ND ND 0 2 0.0
PTEN ND ND ND 0 2 0.0
TLE1 ND ND ND 0 2 0.0
TJP1 ND ND ND 0 1 0.0
Total 18 201 9.0 505 857 58.9
SD, significantly different based on a two-sample 1D KS test, P < 0.01; ND, not determined.JCB • VOLUME 187 • NUMBER 6 • 2009   806
be an exception is VEGFA, which repositioned only in cancers 
where it was amplified. The degree of genomic instability in a   
cancer also did not correlate with the number of genes that re-
positioned (Table S2). Furthermore, the likelihood of a locus to 
reposition in breast cancer was not related to the gene’s genomic 
context because no correlation between propensity to reposition 
and gene density in the surrounding genome region was found 
(P = 0.64, t test; Table S1).
Repositioning events are specific to cancer
Because genomes can spatially reorganize in disease states other 
than cancer (Borden and Manuelidis, 1988; Meaburn et al., 2007), 
and ERBB2 on HSA 17 (C1 and C6), HES5 and PTGS2 on   
HSA 1 (C1 and C4), MYC and HEY1 on HSA 8 (C2), and 
CCND1 and MMP1/3/12 on HSA 11 (C3; Figs. 2 and S2). Fur-
ther evidence for the specificity of repositioning events is indi-
cated by the finding that individual tumors exhibited distinct 
numbers and sets of reorganized genes, with the proportion of 
repositioned genes varying from 18% (3/16 in C1) to 100% (8/8 
in C8; Figs. 1, 2, and S2). The apparent cancer-specific reposi-
tioning events are not caused by genomic instability, which is 
often associated with cancer, because repositioning did not cor-
relate with alterations in gene copy number (Table S2; P < 0.02, 
using Yates correlated 
2 analysis). The only gene that seems to 
Figure 3.  Gene repositioning is specific to cancer. (A) Cumulative RRDs for the indicated genes in noncancerous breast tissues (black) and their mean 
distribution in normal breast tissue (red). (B) Pairwise statistical comparisons of RRDs between individual normal (N1–11) and noncancerous disease (B1–6; 
B1 and B2, B6 hyperplasia, and B3–5 fibroadenoma) breast tissues using the two-sample 1D KS test.807 Cancer-specific spatial gene positioning • Meaburn et al.
approach, we sought to test whether the genes that undergo re-
positioning in cancerous tissue could be used in the identification 
of cancer samples. To this end, we generated a standard RRD 
for each gene by pooling positioning data from all available 
normal tissues (see Materials and methods). We compared the 
position of genes in our known cancer samples to this standard-
ized normal RRD (Fig. S3 and Table III). The position of HES5 
was significantly different from its standardized distribution in 
normal tissues in all 13 cancer tissues (Table III). Similarly, the 
distributions of HSP90AA1 and TGFB3 were distinct in 81.8% 
(9/11) and 78.5% (11/14) of cancers, respectively, compared 
with the standard distribution in normal samples (Table III).   
A lower, yet still significant, fraction of 64–73% of cancers 
showed differential distribution of the remaining five genes 
(8/11 for MYC, 10/14 for ERBB2, 9/13 for FOSL2, 9/13 for 
CSF1R, and 9/14 for AKT1), compared with their standard dis-
tribution. The false negative rate, defined as the percentage of 
cancer tissues exhibiting a gene distribution indistinguishable 
from the standard normal distribution, ranged from 0% (0/13 
cancers) for HES5 to 35.7% (5/14 cancers) for AKT1 (Tables III 
and IV). To determine the false positive rate for the detection of 
cancer samples, we compared the RRDs of these genes in both 
normal and noncancerous breast disease tissues to the pooled 
it is possible that the repositioning events we detected in the can-
cer tissues are not specific to carcinogenesis per se, but instead 
represent a general response to disease. To test this, we analyzed 
the RRDs of the eight genes that are robustly repositioned in can-
cer tissues (HES5, HSP90AA1, AKT1, FOSL2, TGFB3, ERBB2, 
MYC, and CSF1R) in breast tissue with the noncancerous breast 
diseases hyperplasia or fibroadenoma (Fig. 3 and Table I). The 
positioning of genes in the noncancerous disease samples was 
similar to that in normal tissue, with only 11.2% (32/285) of 
cross-comparisons showing differences (two-sample 1D KS test; 
P < 0.01). For seven of the eight genes, the rates of significantly 
different cross-comparisons were low and ranged from 0% (0/30; 
MYC) to 8.6% (3/35; HES5, FOSL2, and AKT1). Similarly to 
normal tissues, ERBB2 had a higher rate of differences, with 
37.8% (17/45) of the cross-comparisons being statistically differ-
ent. We conclude that repositioning of most genes is specific to 
cancer and is not a general indicator of disease.
Gene positioning as a cancer marker
Differential radial repositioning of some genes in cancer tis-
sues opens up the possibility of using spatial positioning pat-
terns to identify cancer tissues, including for possible use   
in diagnostic applications. As a proof-of-principle for this 
Table III.  Comparison of individual cancer and normal tissues to a standard normal distribution
Individual p-values for the comparison of RRDs in individual cancer tissues (C1–14) or normal tissues (N1–11) to a pooled normal distribution (two-sample 1D KS 
test). Orange (P < 0.01) and red (P < 0.001): significantly different radial positions; blue (P > 0.05) and light blue (0.01 < P < 0.05): statistically similar distributions. 
ND, not determined.JCB • VOLUME 187 • NUMBER 6 • 2009   808
sitioning of at least one of the genes in all tumors (Table VI).   
A further 14 combinations showed repositioning of at least one 
of the genes in ≥85% of the tumors, a rate higher than seven of 
the eight genes when used individually (Table III). Among the 
possible 35 combinations of three genes, 22 showed reposition-
ing of at least one gene in all tumors (Table S3). The overall 
false negative rates of all multiplexed genes was 10.2% (29/284 
combinations;  range  of  0–21.4%)  for  two  genes  and  4.9% 
(19/385; range of 0–14.3%) for three genes (Tables VI and S3). 
The overall false positive rate for using two genes combined 
was 18.4% (37/201), and the rate for the three gene combina-
tions was 27.4% (81/296; Tables III and V). As with the single   
gene analysis, the false positive rate was higher in the non-
cancerous breast disease tissue than in normal tissue. For the two 
gene combinations, the false positive rate in normal tissue was 
8.1% (9/111), whereas in noncancerous breast disease tissues, 
it was 31.1% (28/90). For the three gene combinations, the false 
positive rate in normal tissue was 10.6% (16/151) and 44.8% 
(65/145)  in  noncancerous  breast  disease  tissue.  Collectively, 
these results indicate that the spatial positioning of individual 
or combined genes is a robust method to classify an individual 
tissue sample as normal or cancerous.
Discussion
In this study, we have identified several genes that are differ-
entially positioned in invasive breast cancers compared with 
normal tissue, and we show that determination of their positioning 
normal distribution (Tables III–V). In 8.2% (8/97) of compari-
sons, there were positioning differences, with the frequency of 
repositioning  higher  in  noncancerous  breast  disease  tissues 
(15%; 6/40) than in normal tissues (3.5%; 2/57). The incidence 
of repositioning in noncancerous tissue for individual genes 
ranged from 0% for four of the genes (TGFB3, MYC, FOSL2, 
and CSF1R) to 28.6% for ERBB2 (4/14 tissues; P ≤ 0.0046; 
Fig. S3 and Tables III–V).
Typical cancer specimens used for diagnosis may contain 
a mixture of normal and cancer cells, wherein the normal cells 
would dilute any repositioning events detected and could result 
in false negatives. To determine the minimal fraction of cancer 
cells required in a sample, we generated datasets containing 
varying proportions (10–70%) of cancer nuclei. To this end,   
images of a total of 160 normal or cancer nuclei were randomly 
selected from multiple tissues and combined into a single data-
set; then the RRD of HES5 was determined using our standard 
procedure (see Materials and methods; Fig. S1). Differential 
positioning of HES5 could be detected in datasets containing up 
to 40% normal nuclei (P ≤ 0.001), demonstrating that tissue 
heterogeneity does not preclude accurate detection of gene po-
sition and identification of cancer tissues.
Repositioning of gene combinations
Although a single gene, HES5, was repositioned in all tested 
cancer samples, we explored whether combinatorial use of the 
other seven genes could be used for the detection of cancer sam-
ples. Among 21 combinations of two genes, four showed repo-
Table IV.  Single gene false positive and negative rates
Gene False negatives Normal tissue false positives Noncancerous breast disease tissue  
false positives
Total false positives
HES5 0/13 (0%) 0/7 (0%) 1/5 (20%) 1/12 (8.3%)
HSP90AA1 2/11 (18.2%) 0/6 (0%) 2/5 (40%) 2/11 (18.2%)
TGFB3 3/14 (21.4%) 0/8 (0%) 0/5 (0%) 0/13 (0%)
MYC 3/11 (27.3%) 0/6 (0%) 0/5 (0%) 0/11 (0%)
ERBB2 4/14 (28.6%) 1/9 (11.1%) 3/5 (60%) 4/14 (28.6%)
FOSL2 4/13 (30.8%) 0/7 (0%) 0/5 (0%) 0/12 (0%)
CSF1R 4/13 (30.8%) 0/7 (0%) 0/5 (0%) 0/12 (0%)
AKT1 5/14 (35.7%) 1/7 (14.3%) 0/5 (0%) 1/12 (8.3%)
Total 25/103 (24.3%) 2/57 (3.5%) 6/40 (15.0%) 8/97 (8.2%)
The number (and percentages) of tissues that give either a false negative or false positive result. For a false negative, a gene has a similar RRD in a cancer tissue to 
that of the pooled normal distribution (two-sample 1D KS test, P > 0.01). A false positive is scored when a gene has a statistically different RRD than that of the pooled 
normal in noncancerous breast tissues (P < 0.01).
Table V.  Comparison of individual noncancerous breast disease tissues to standard normal distributions
Individual p-values for each comparison between an individual tissue and the pooled normal distribution (two-sample 1D KS test) for a given gene. Orange (P < 0.01) 
and red (P < 0.001): significantly different radial positions; blue (P > 0.05) and light blue (0.01 < P < 0.05): similar radial positions. ND, not determined.809 Cancer-specific spatial gene positioning • Meaburn et al.
between individuals. Furthermore, we demonstrate that cancer 
tissues can accurately be identified by comparison to a stan-
dardized normal gene distribution. This is critical for clinical 
applications because normal tissue is not necessarily available 
from a proband. Moreover, the fact that the positioning of gene 
loci in tissue from healthy individuals is identical to that in mor-
phologically normal tissue adjacent to a tumor indicates that 
normal tissue from a proband can equally serve as a reference.
Cancer detection using spatial genome positioning prom-
ises to be a robust method. We discovered a single gene, HES5, 
that detected invasive breast cancer tissue with near 100% accu-
racy. HES5 is both a primary target and an effector of the Notch 
signaling pathway, and has been implicated in cancer (Iso et al., 
2003; Hallahan et al., 2004; Liu et al., 2007). The overall rates 
of false positives and false negatives for single markers were 
low (8.2% and 24.3%, respectively). In addition, we identified 
several combinations of two or three multiplexed markers that 
detect cancerous tissues with no false negative signals and a 
low rate of false positive outcomes. The false detection rate of 
this approach compares favorably to the current, standard breast 
cancer diagnostic tests, such as fine-needle aspiration cytology 
and core-needle biopsy cytology, for which false positive rates 
of 0–44% and 0–13.4%, respectively, and false negative rates 
of 1.3–39% and 4.5–17%, respectively, have been described 
(Arisio et al., 1998; Young et al., 2002; Chaiwun and Thorner, 
2007; Ciatto et al., 2007; Bukhari and Akhtar, 2009); however, 
these rates, in contrast to our analysis, also include specimen 
sampling errors. Importantly, however, the broad range in false 
detection rates in conventional cytological assays is also largely 
related  to  the  experience  of  the  examining  cytopathologist. 
The use of spatial genome positioning for detection of tumors 
should reduce human error in making a diagnosis because the 
method is not based on subjective criteria but gives a quantifi-
able readout, making it independent of the expertise of the in-
dividual performing the analysis. A distinct advantage of this 
approach is the very small quantity of material required. Differ-
ences in spatial positioning were routine detected by analysis 
of 100–200 cells and despite inherent heterogeneity in samples, 
although a requirement appears to be that at least 60% of the 
nuclei analyzed are cancerous. This approach is suitable for 
adaptation in a routine laboratory setting, as all individual steps   
of the procedure rely on standard methods including paraffin 
pattern reliably detects cancerous tissues. We suggest that 
interphase spatial genome positioning may be useful for diag-
nostic applications.
Spatial reorganization of the genome has previously been 
linked to cancer and genomic instability (Cremer et al., 2003; 
Taslerová et al., 2003, 2006; Murmann et al., 2005; Wiech et al., 
2005, 2009; Petrova et al., 2007; Sengupta et al., 2007; Meaburn 
and Misteli, 2008). With the exceptions of a few chromo-
somal translocations, however, the previously described cancer-
associated  spatial  genome  repositioning  events  are  relatively 
minor and often involve large genome regions (Cremer et al., 
2003; Wiech et al., 2005; Meaburn and Misteli, 2008; Wiech et al., 
2009). Here, we have systematically identified cancer-specific 
repositioning events of several gene loci. Interestingly, the repo-
sitioned genes differ from four previously identified genes that 
reposition in a 3D culture in vitro model system of early breast 
cancer (Meaburn and Misteli, 2008). Although AKT1 and ERBB2 
repositioned in both the 3D cell culture model and in tissue 
specimens, two other genes, BCL2 and VEGFA, repositioned in 
the cell culture model but not in a significant proportion of cancer 
tissues. In contrast, TGFB3 did not reposition in the cell culture 
model of cancer, but was repositioned in a large majority of 
cancer tissues. Notably, we find the degree of repositioning to 
be generally larger in tissues compared with the cell culture system. 
In agreement with previous findings in the 3D culture in vitro 
model system (Meaburn and Misteli, 2008) and with observa-
tion of a general conservation of spatial positioning of the ge-
nome in cancer cells (Parada et al., 2002; Cremer et al., 2003), 
we find that the repositioning of genes in breast cancer tissues is 
gene specific, independent of numerical abnormalities and un-
related to gene density in the proximity of the repositioned gene. 
Although not explicitly tested here, we have previously found in 
a 3D breast cancer model system that there is no correlation 
between gene activity and likelihood of repositioning of an in-
dividual locus (Meaburn and Misteli, 2008). We find that the re-
positioning of many genes is specific to cancer and does not 
occur in noncancerous breast disease nor within the normal tissue 
adjacent to a tumor.
Identification  of  genes  that  are  differentially  localized 
in normal and cancer cells allows for the possibility of using 
spatial gene positioning as a diagnostic tool. As required for 
such an application, we find low variability of gene positioning 
Table VI.  Gene multiplexing
The number (and percentage) of cancers where at least one of the indicated pair of genes repositioned, compared to the pooled normal distribution. Red boxes 
indicate a 100% detection rate; pink, >90%; yellow, >80%; and green, >70%. ×, not applicable.JCB • VOLUME 187 • NUMBER 6 • 2009   810
The nuclei were co-denatured with the FISH probes at 85°C for 10 min 
and left to hybridize overnight at 37°C in a humid container. The next 
day, three 5-min washes in 50% formamide/2× SSC at 45°C followed by 
three 5-min washes in 1× SSC at 60°C were performed, and the slides 
were placed in 0.1% Tween 20/4× SSC at RT to cool. To block, the slides 
were incubated for 15–20 min in 3% bovine serum albumin (Sigma- 
Aldrich)/0.1% Tween 20/4× SSC. Detection antibody anti–digoxigenin-
rhodamine (Roche) and fluorescein-avidin DN (Vector Laboratories) were 
diluted 1:200 in blocking solution and incubated with the tissues for 2 h 
at 37°C. Slides were mounted in DAPI-containing Vectashield mounting 
medium (Vector Laboratories) after three 5-min washes in 0.1% Tween 20/ 
4× SSC at RT.
Image acquisition
For analysis of the FISH signals, tissue sections were imaged using a micro-
scope (IX70; Olympus) controlled by a Deltavision System (Applied Preci-
sion) with SoftWoRx 3.5.1 software (Applied Precision) and fitted with a 
charge-coupled device camera (CoolSnap; Photometrics). We used a 60×, 
1.4 NA oil objective lens and an auxiliary magnification of 1.5. Z stacks 
were acquired to cover the thickness of the tissue section with a step size of 
0.2 µm or 0.5 µm in the z direction. The increase of step size to 0.5 µm 
gave identical results to 0.2 µm. Images were acquired at a 1,024 × 1,024 
pixel resolution, with a pixel size equivalent to 0.07427 µm in x and y. De-
convolution was performed on the image stacks using the following settings 
of SoftWoRx 3.5.1: enhance ratio (aggressive) method, 10 cycles, medium 
noise filtering, border rolloff (voxel) set to 16, size for z transformation set 
to 128, Wiener filter enhancement set at 0.9, Wiener filter smoothing set at 
0.8, and intensity scale factor set at 1. Maximum intensity projections of the 
deconvolved stacks were generated and analyzed for the radial distribution 
of the FISH signals, as described in the next section.
Quantitative analysis of FISH signal distributions
Initially, images were contrast-enhanced based on visual inspection, and 
individual cell nuclei from the blue color channel were manually delin-
eated using Photoshop 7.0 (Adobe). Manual segmentation was required 
to avoid nuclei that were overlapping and because of the close proxim-
ity of nuclei in many tissues. The automatic detection of FISH signals 
was performed as described previously (Meaburn and Misteli, 2008; 
Takizawa et al., 2008a); in brief, a three-stage process was used in-
volving: (1) noise reduction, (2) segmentation, and (3) post-processing.   
(1)  Background  noise  was  removed  in  each  channel  by  applying  an 
adaptive  nonlinear  noise  reduction  technique  (“SUSAN”;  Smith  and 
Brady, 1997). (2) A fuzzy-C-means clustering algorithm was applied on 
the noise-reduced images to probabilistically assign each image picture 
element (pixel) into two classes. The two classes corresponded to back-
ground and objects in the image. The images from this process were 
segmented into binary images whereby each pixel with >50% probabil-
ity of being in the object class was classified as corresponding to actual 
objects in the specimen, whereas the remaining pixels were classified 
as background. The integrated intensities of each group of contiguous 
object pixels were calculated, and those groups that exceeded a thresh-
old value, which was calculated automatically by the isodata threshold 
method in DIPimage toolbox (Technical University of Delft), were consid-
ered to correspond to individual FISH signals.
For quantification of the spatial distributions of FISH signals, the 
following procedure was used: for each segmented nucleus, the binary 
Euclidean distance transform (EDT) was computed (Danielsson, 1980). The 
EDT is a morphological operation that assigns each pixel in the nucleus a 
Euclidean distance to the closest boundary point; i.e., the EDT value as-
signed to each pixel in a segmented nucleus equals the shortest distance 
to the edge of the nucleus. To account for variations in nuclear size, this 
distance-transformed image was normalized with the maximum EDT value 
for the given nucleus, such that the normalized EDT values varied between 
0 (nuclear periphery) and 1 (nuclear center). The position of each FISH 
signal was defined by its geometric gravity center, and the normalized 
EDT value corresponding to that position was used to determine the relative 
radial position of each signal. Using this method, no assumption regarding 
nuclear shape is made when determining the radial position of a gene. In 
addition, the number of red and green FISH signals in each nucleus was 
recorded. All analysis tools were implemented using custom software writ-
ten in MATLAB (Mathworks, Inc.) with DIPimage toolbox.
Statistical analysis
All alleles in a nucleus were included for analysis, and nuclei were in-
cluded regardless of the number of alleles present for a gene, unless the 
embedding of biopsy material, FISH detection, and image   
analysis methods. We obtained the required 100–200 cells for 
analysis from a single 5-µm-thick slice of a biopsy section or 
2.5-mm tissue microarray (TMA) core, and we typically used 
12–30 image fields containing a total of 200–1,000 cells to   
obtain the required 100–200 analyzable cells. Imaging of a typical 
sample takes no longer than 60 min, and can be automated.
If validated in a larger number of samples, we envision 
that this approach may be a useful first molecular indicator of 
cancer after an abnormal mammogram using tissue from a core 
needle biopsy, and would be used in combination with standard 
pathological  indicators  such  as  gene  amplification.  Interest-
ingly, ERBB2 and MYC, which are currently both screened for 
amplification status by FISH in the diagnosis of breast cancer, 
were both repositioned in a large proportion of cancer tissues. 
The proof of concept we describe here lays the foundation for 
future studies to examine whether gene positioning analysis 
will  reveal  differences  not  apparent  by  gross  morphological 
changes detected by pathologists and whether it will be useful 
in identifying early stage cancers. Moreover, the observed vari-
ability in gene repositioning patterns between individual can-
cers in our analysis hints at the promise of spatial positioning 
patterns to go beyond simply discriminating cancerous from 
normal tissues and implies the possibility of a prognostic value, 
such as distinguishing between cancer subtypes or survival out-
comes. Finally, our method of cancer diagnosis is not limited to 
breast cancer and may be applied to any cancer type in which 
repositioned genes can be identified.
Materials and methods
FISH
4–5-µm-thick, formalin-fixed, paraffin-embedded human breast tissue sec-
tions  containing  morphologically  normal  tissue,  invasive  carcinoma,  or 
noncancerous breast disease (hyperplasia and fibroadenoma) were ob-
tained from the AIDS and Cancer Specimen Resource or purchased from 
US Biomax, Inc., Imgenex Corp., Capital BioSciences, Inc., and BioChain 
Institute, Inc. (Table I). The tissues were in the form of standard single tissue 
slides, with the exceptions of tissues N6, C7–13, and B1–6, which formed 
part of a TMA (catalog no. Z7020010, core size of 2.5 mm; BioChain 
Institute, Inc.). The FISH procedure was identical for all specimens, except 
where stated otherwise.
To generate FISH probes, the bacterial artificial chromosome (BAC) 
clones detailed in Table S1 (BACPAC Resources Center) were labeled by nick 
translation with dUTPs conjugated with either biotin (Roche) or digoxigenin 
(Roche) as described in detail in Parada et al. (2002b). Dual-probe FISH   
experiments were routinely performed using 600–800 ng each of digoxigenin- 
and biotin-labeled probe DNA, 10 µg of human COT1 (Roche), and 40 µg 
tRNA (Sigma-Aldrich), then resuspended in 10 µl of hybridization mix (10% 
[wt/vol] dextran sulfate [Sigma-Aldrich], 50% [vol/vol] formamide [Sigma-
Aldrich], 2× SSC, and 1% [wt/vol] Tween 20 [Sigma-Aldrich]).
Slides  were  dewaxed  by  two  30-min  incubations  in  Xylene 
(Mallinckrodt Baker, Inc.). Immediately before this treatment, TMA slides 
were baked at 60°C for 1 h. The tissues were rehydrated with sequential 
5-min incubations in an ethanol series (100%, 90%, and 70%) followed 
by 10 min in PBS. Slides were then boiled in the microwave (1,000 W 
for 10 min in 700 ml of solution) in 0.01 M sodium citrate, pH 6, and 
left at RT until cooled to 37°C. Subsequently, the tissue sections were 
incubated at 37°C in 10 µg/ml RNase A (Sigma-Aldrich)/2× SSC for   
15 min and washed for 5 min in PBS. After this, the tissues were sub-
jected to incubation with 0.25 mg/ml proteinase K (Sigma-Aldrich) at 
37°C for 10 min 30 s for TMA slides, 11 min for individual morphologi-
cally normal breast tissues, and 10 min for the single cancerous tissues. 
After a brief rinse in PBS, the slides were taken through a dehydrating 
ethanol series (70%, 90%, and100%; 5 min each) and left to air dry. 811 Cancer-specific spatial gene positioning • Meaburn et al.
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nucleus contained no FISH signals for either gene. The relative radial posi-
tions of FISH signals across multiple nuclei of the same specimen were 
combined to generate RRDs. The RRDs from different samples were then 
compared using a two-sample 1D KS test. To account for the multiple com-
parisons, differences were considered significant if there was <1% proba-
bility that the two distributions arose from the same parent distribution (P < 
0.01). 100 or 200 randomly chosen nuclei from a dataset gave highly 
similar results to 526 or 876 nuclei from the same dataset (0.88 ≤ P ≤ 
0.96; Fig. S1). Although 25 or 50 nuclei did not reach significance when 
compared with the full dataset of 526 or 876 nuclei (0.22 ≤ P ≤ 0.68), a 
greater variability was seen; thus, 110–220 nuclei per gene per tissue 
were analyzed (200–220 nuclei for AKT and TGFB3 in N8–10, BCL2 and 
VEGFA in N4 and N10, CCND1 and ERBB2 in N4, N8–10, and for these 
six genes in C2, C5 and C6; ERBB2 was analyzed in 161 nuclei in C13; 
110–143 nuclei were analyzed for the remaining datasets), with the ex-
ception of HSP90AA1 in C11, where 88 nuclei were analyzed. The num-
ber of nuclei for the pooled normal datasets was as follows: HES5, n = 
921 nuclei from a total of seven individuals; HSP90AA1, n = 797 nuclei 
from  six  individuals;  AKT1,  n  =  1,149  nuclei  from  seven  individuals; 
FOSL2, n = 919 nuclei from seven individuals; TGFB3, n = 1,269 nuclei 
from eight individuals; ERBB2, n = 1,406 nuclei from nine individuals; 
CSFR1, n = 885 nuclei from seven individuals; and MYC, n = 756 nuclei 
from six individuals. Pilot experiments demonstrated high reproducibility 
between repeat experiments (typically 0.65 ≤ P ≤ 0.81).
Datasets with varying ratios of normal and cancer nuclei, for the 
gene HES5, were blindly generated and analyzed. Each dataset contained 
a total of 160 individual nuclei with varying ratios (10–70%) of cancer/
normal cells. A master dataset containing 200 randomly selected nuclei 
each from known normal or cancer samples, where HES5 had been de-
tected, was first generated. To ensure there was no biasing toward a par-
ticular tissue, the randomly selected nuclei were taken from four different 
normal tissues and 12 different cancer tissues, with approximately equal 
numbers of nuclei used from each tissue of the same type (50 nuclei per 
tissue for normal and 17 nuclei per tissue for cancer tissues). From these 
pools of nuclei datasets with varying ratios of cancer, nuclei were gener-
ated. The person mixing the nuclei had no prior knowledge on which of the 
master datasets contained normal and which contained the cancer nuclei. 
Furthermore, the individual performing the RRD analysis was blinded as to 
the ratio of nuclei from each of the master datasets. Cumulative RRDs from 
these datasets were generated and compared with the pooled normal dis-
tribution of HES5 using the two-sample 1D KS test. P < 0.01 was consid-
ered significant.
Statistical significance between the incidence of repositioning and 
changes to copy number were determined by Yates correlated 
2 analysis, 
where a P value < 0.05 was considered significant. The null hypothesis 
being tested was that a gene repositioned in cancer due only to genomic 
instability. Data were used from all 20 genes. For this analysis, a gene was 
considered to reposition in a cancer tissue if the majority of cross-comparisons 
between the individual cancer tissue and the individual normal tissues were 
significantly different (P < 0.01). A gain in copy number for a gene was 
assumed if >20% of nuclei in a tissue had three or more signals; a loss of 
copy number for a gene was recorded if ≥40% of nuclei in the tissue had 
only one allele detected. Using these cut-off values, normal tissues were 
never classified as having a copy number variation.
To probe for an effect of gene density on repositioning probabil-
ity, the number of genes 1 MB on either side a gene were calculated 
using  data  from  http://www.ncbi.nlm.nih.gov/mapview/map_search 
.cgi?taxid=9606. The statistical significance between the local gene densi-
ties for genes that have a propensity to reposition in cancer tissues com-
pared  with  normal  (HES5,  HSP90AA1,  TGFB3,  MYC,  ERBB2,  FOSL2, 
CSF1R, and AKT1) and those loci that do not (VEGFA, CCND1, HES1, 
PTGS2, MMP1/3/12, ZNF217, BCL2, HEY1, BRAC1, PTEN, TLE1, and 
TJP1) was assessed using a two-tailed Student’s t test in Excel (Microsoft).
Online supplemental material
Fig. S1 shows the determination of appropriate sample size and of the 
minimal fraction of cancer cells required for analysis. Fig. S2 contains 
additional  data  showing  loci-specific  reorganization  of  the  genome  in 
breast cancer. Fig. S3 shows standardized pooled normal distributions, 
with individual normal and cancer specimens for comparison. Table S1 
provides  additional  information  about  the  candidate  genes.  Table  S2 
demonstrates that repositioning events are not due to numerical changes. 
Table S3 provides false negative rates based on combinations of three 
genes.  Online  supplemental  material  is  available  at  http://www.jcb 
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